Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 24;24(21):15530. doi: 10.3390/ijms242115530

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

ZNF714 status in TCGA specimens. Boxplot representation of ZNF714 expression (A) and promoter methylation (C) in normal (blue) and tumor (red) samples across various TCGA cohorts based on the UALCAN database. Student’s t-test was used to assess the significance of the difference; * <0.05, ** <10⁻⁵, *** <10⁻¹⁰, n.d. no data. (B) ZNF714 expression differs significantly among molecular subtypes in the majority of TCGA cohorts. (D) ZNF714 promoter methylation level correlates negatively with ZNF714 expression. (E) ZNF714 expression is higher in most of the tumors with mutated p53. (F,G) Mutational status of ZNF714 throughout various tumor types. (H) ZNF714 expression correlates with Copy Number Variation (CNV) status. (I) Genome Browser visualization of ZNF714 neighborhood 1 Mb upstream and downstream from TSS and TTS, respectively. The surrounding genes belong to the zinc finger family. (J) Pearson’s correlation analysis demonstrates the co-expression of ZNF714 and surrounding genes. (K) Transcription factors (TFs) binding to the top 100 genes with similar expression patterns compared to ZNF714 expression identified via EnrichR Encode and ChEA Consensus TFs from ChIP-X analysis. Adrenocortical carcinoma (ACC); Acute Myeloid Leukemia (AML); bladder urothelial carcinoma (BLCA); breast invasive carcinoma (BRCA); cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC); cholangiocarcinoma (CHOL); Colon adenocarcinoma (COAD); lymphoid neoplasm diffuse large B-cell lymphoma (DLBC); esophageal carcinoma (ESCA); glioblastoma multiforme (GBM); head and neck squamous cell carcinoma (HNSC); kidney chromophobe (KICH); kidney renal clear cell carcinoma (KIRC); kidney renal papillary cell carcinoma (KIRP); brain lower-grade glioma (LGG); liver hepatocellular carcinoma (LIHC); lung adenocarcinoma (LUAD); lung squamous cell carcinoma (LUSC); mesothelioma (MESO); ovarian serous cystadenocarcinoma (OV); pancreatic adenocarcinoma (PAAD; prostate adenocarcinoma (PRAD); pheochromocytoma and paraganglioma (PCPG); rectum adenocarcinoma (READ); sarcoma (SARC); skin cutaneous melanoma (SKCM); stomach adenocarcinoma (STAD); testicular germ cell tumor (TGCT); thyroid carcinoma (THCA); thymoma (THYM); uterine corpus endometrial carcinoma (UCEC); uterine carcinosarcoma (UCS); uveal melanoma (UVM).